Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in ChinaCompleted
NCT06099028N/AUpdated Jan 23, 2024
Sponsor: Peking University First Hospital
Heart Failure
China
Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsCompleted
NCT02564900Phase 1Updated Jan 22, 2024
Sponsor: Daiichi Sankyo Co., Ltd.
Advanced Solid Tumors
United States, Japan
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompleted
NCT02163733Phase 1Updated Jan 22, 2024
Sponsor: AstraZeneca
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
France, South Korea, Spain, United Kingdom
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerCompleted
NCT00494234Phase 2Updated Jan 19, 2024
Sponsor: AstraZeneca
Breast Neoplasms
United States, Australia, Canada, Germany, Israel +3 more
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2Withdrawn
NCT05482074Phase 2Updated Jan 19, 2024
Sponsor: Dana-Farber Cancer Institute
Recurrent Metastatic Melanoma · Cutaneous Melanoma · Mucosal Melanoma · Uveal Melanoma
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:Completed
NCT04836975N/AUpdated Jan 18, 2024
Sponsor: AstraZeneca
Lung Cancer
Saudi Arabia
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis PatientsCompleted
NCT04483947Phase 1Updated Jan 17, 2024
Sponsor: AstraZeneca
Non-alcoholic Steatohepatitis (NASH)
United States
Olaparib Maintenance Therapy in Metastatic Breast CancerUnknown
NCT05629429Phase 2Updated Jan 17, 2024
Sponsor: National Taiwan University Hospital
Metastatic Breast Cancer
Taiwan
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompleted
NCT02117167Phase 2Updated Jan 10, 2024
Sponsor: UNICANCER
Non-small Cell Lung Cancer Metastatic
France
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With AsthmaCompleted
NCT04673630Phase 1Updated Jan 8, 2024
Sponsor: AstraZeneca
Asthma
Hungary, South Africa, United Kingdom
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer PatientsCompleted
NCT02879617Phase 2Updated Jan 5, 2024
Sponsor: Academic Thoracic Oncology Medical Investigators Consortium
Non-Small Cell Lung Cancer NSCLC
United States
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy VolunteersCompleted
NCT05714254Phase 1Updated Jan 5, 2024
Sponsor: AstraZeneca
Chronic Pain
Germany
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsCompleted
NCT04361825Phase 2Updated Jan 3, 2024
Sponsor: Se-Hoon Lee
Small Cell Lung Cancer
South Korea
Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer SubjectsCompleted
NCT04939662Phase 2Updated Jan 2, 2024
Sponsor: Se-Hoon Lee
Lung Cancer
South Korea
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2Completed
NCT03782259Phase 4Updated Dec 29, 2023
Sponsor: University of Washington
Type 2 Diabetes Mellitus · Myocardial Fibrosis · Myocardial Inflammation
United States
IBS-C Questionnaire StudyCompleted
NCT04968652N/AUpdated Dec 28, 2023
Sponsor: AstraZeneca
Irritable Bowel Syndrome With Constipation · Functional Constipation
China
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseCompleted
NCT05511025Phase 1Updated Dec 26, 2023
Sponsor: AstraZeneca
Healthy Participants
United States
Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoUnknown
NCT05917561Phase 2Updated Dec 22, 2023
Sponsor: University Hospital, Bordeaux
Vitiligo
France
A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During PregnancyWithdrawn
NCT05847140N/AUpdated Dec 22, 2023
Sponsor: AstraZeneca
Pregnancy · Pregnant Women · Pregnancy Outcome
Phase I AZD2281/Cisplatin in Advanced Solid Tumour PatientsCompleted
NCT00782574Phase 1Updated Dec 21, 2023
Sponsor: AstraZeneca
Advanced Solid Tumors
United States, Spain
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese SubjectsCompleted
NCT04588727Phase 1Updated Dec 18, 2023
Sponsor: AstraZeneca
Cardiovascular Disease
United States
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With HyperlipidaemiaCompleted
NCT04964557Phase 2Updated Dec 15, 2023
Sponsor: AstraZeneca
Hyperlipidaemia
United States, Czechia, Denmark, Hungary, Netherlands +3 more
Anticoagulant-associated Intracranial HemorrhageUnknown
NCT06168838N/AUpdated Dec 13, 2023
Sponsor: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Anticoagulant-induced Bleeding · Intracranial Hemorrhages
Mexico
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and DigoxinCompleted
NCT05395117Phase 1Updated Dec 13, 2023
Sponsor: AstraZeneca
Healthy Participants
United States
A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese ParticipantsCompleted
NCT03276052Phase 1Updated Dec 11, 2023
Sponsor: AstraZeneca
Healthy Volunteers
China

Previous page Next page